Abstract
The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 3 weeks. Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Acridines / administration & dosage
-
Acridines / therapeutic use*
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Carboplatin / therapeutic use
-
Cisplatin / therapeutic use
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Middle Aged
-
Ovarian Neoplasms / drug therapy*
-
Pyrazoles / administration & dosage
-
Pyrazoles / therapeutic use*
Substances
-
Acridines
-
Antineoplastic Agents
-
Pyrazoles
-
Carboplatin
-
NSC 366140
-
Cisplatin